$PSTX
Poseida Therapeutics, Inc.

2020 Q3 Form 10-Q Financial Statement

#000156459020053578 Filed on November 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2019 Q4 2019 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.460M
YoY Change
% of Gross Profit
Research & Development $27.02M
YoY Change
% of Gross Profit
Depreciation & Amortization $690.0K $730.0K
YoY Change 386.67%
% of Gross Profit
Operating Expenses $33.47M $20.76M
YoY Change 61.22%
Operating Profit -$33.47M -$20.76M
YoY Change 61.22%
Interest Expense $848.0K $935.0K
YoY Change -9.3%
% of Operating Profit
Other Income/Expense, Net -$92.00K $744.0K
YoY Change -112.37%
Pretax Income -$34.41M -$20.95M
YoY Change 64.24%
Income Tax
% Of Pretax Income
Net Earnings -$34.41M -$20.95M
YoY Change 64.24%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$626.0K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $341.5M
YoY Change
Cash & Equivalents $66.27M $87.78M $94.03M
Short-Term Investments $275.2M
Other Short-Term Assets $5.800M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $347.3M $127.2M
YoY Change 290.12%
LONG-TERM ASSETS
Property, Plant & Equipment $48.80M $10.86M
YoY Change 219.35%
Goodwill $4.228M $4.228M
YoY Change
Intangibles $1.320M $1.320M
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.548M $3.411M
YoY Change -2.54%
Total Long-Term Assets $57.87M $19.82M
YoY Change 58.54%
TOTAL ASSETS
Total Short-Term Assets $347.3M $127.2M
Total Long-Term Assets $57.87M $19.82M
Total Assets $405.2M $147.0M
YoY Change 225.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.256M $4.929M
YoY Change 69.97%
Accrued Expenses $25.70M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00 $3.000M
YoY Change
Total Short-Term Liabilities $29.77M $21.86M
YoY Change 68.12%
LONG-TERM LIABILITIES
Long-Term Debt $29.06M $26.14M
YoY Change 36.86%
Other Long-Term Liabilities $1.081M $5.421M
YoY Change -68.48%
Total Long-Term Liabilities $30.14M $31.56M
YoY Change -13.06%
TOTAL LIABILITIES
Total Short-Term Liabilities $29.77M $21.86M
Total Long-Term Liabilities $30.14M $31.56M
Total Liabilities $109.3M $74.33M
YoY Change 50.47%
SHAREHOLDERS EQUITY
Retained Earnings -$245.7M -$152.2M
YoY Change
Common Stock $541.6M $2.691M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $295.8M -$149.5M -$127.2M
YoY Change
Total Liabilities & Shareholders Equity $405.2M $147.0M
YoY Change 225.93%

Cashflow Statement

Concept 2020 Q3 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$34.41M -$20.95M
YoY Change 64.24%
Depreciation, Depletion And Amortization $690.0K $730.0K
YoY Change 386.67%
Cash From Operating Activities -$29.32M -$35.74M
YoY Change 192.71%
INVESTING ACTIVITIES
Capital Expenditures -$2.800M -$3.210M
YoY Change 409.52%
Acquisitions
YoY Change
Other Investing Activities -$255.3M -$18.66M
YoY Change
Cash From Investing Activities -$258.1M -$21.86M
YoY Change 3369.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 206.5M 7.880M
YoY Change 67.3%
NET CHANGE
Cash From Operating Activities -29.32M -35.74M
Cash From Investing Activities -258.1M -21.86M
Cash From Financing Activities 206.5M 7.880M
Net Change In Cash -80.85M -49.72M
YoY Change 511.56%
FREE CASH FLOW
Cash From Operating Activities -$29.32M -$35.74M
Capital Expenditures -$2.800M -$3.210M
Free Cash Flow -$26.52M -$32.53M
YoY Change 180.92%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4199000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
29770000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21855000
CY2019Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1081000
CY2020Q3 us-gaap Liabilities
Liabilities
109335000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
744000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
216000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146996000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
37534000
CY2019Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
32934785
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Operating Expenses
OperatingExpenses
91189000
CY2020Q3 pstx Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
24315000
CY2019Q4 pstx Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
13926000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000000
CY2020Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
29059000
CY2020Q3 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
23755000
CY2019Q4 pstx Warrant Liabilities Noncurrent
WarrantLiabilitiesNoncurrent
1271000
CY2020Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
55000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25615000
CY2019Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
222173000
CY2020Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2019Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33085827
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2019Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
32934785
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
57013463
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13196419
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13196419
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14449000
CY2019Q3 pstx Business Combination Change In Contingent Consideration Including Related Party Amount
BusinessCombinationChangeInContingentConsiderationIncludingRelatedPartyAmount
1060000
pstx Business Combination Change In Contingent Consideration Including Related Party Amount
BusinessCombinationChangeInContingentConsiderationIncludingRelatedPartyAmount
6683000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
20763000
us-gaap Operating Expenses
OperatingExpenses
62321000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-20763000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91189000
us-gaap Operating Income Loss
OperatingIncomeLoss
-62321000
CY2019Q3 us-gaap Interest Expense
InterestExpense
935000
us-gaap Interest Expense
InterestExpense
2654000
us-gaap Interest Expense
InterestExpense
2633000
CY2020Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1320000
CY2020Q3 us-gaap Goodwill
Goodwill
4228000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3548000
CY2020Q3 us-gaap Assets
Assets
405171000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1256000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
295836000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-245736000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-152221000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-149511000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
405171000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61819509
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61819509
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
541605000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-39000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
19000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2689000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5421000
CY2019Q4 us-gaap Liabilities
Liabilities
74334000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
6000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26140000
CY2019Q4 pstx Deferred Cirm Grant Liability Noncurrent
DeferredCIRMGrantLiabilityNoncurrent
19592000
CY2019Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
37000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-117558000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-93627000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-62914000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2040000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-20954000
pstx Business Combination Contingent Consideration Related Party Amount
BusinessCombinationContingentConsiderationRelatedPartyAmount
2739000
CY2020Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2019Q3 us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
us-gaap Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
0
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-76718000
CY2019Q3 pstx Business Combination Contingent Consideration Related Party Amount
BusinessCombinationContingentConsiderationRelatedPartyAmount
434000
pstx Business Combination Contingent Consideration Related Party Amount
BusinessCombinationContingentConsiderationRelatedPartyAmount
0
us-gaap Net Income Loss
NetIncomeLoss
-62914000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-59000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-8000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-58000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-59000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-8000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-58000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34473000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20962000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93685000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-62917000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.65
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.43
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.06
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
54973788
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12665834
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27324297
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12427367
CY2020Q3 pstx Business Combination Contingent Consideration Related Party Amount
BusinessCombinationContingentConsiderationRelatedPartyAmount
0
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-13334000
CY2019Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
454000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-89580000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-28627000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
607000
CY2019Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5000
CY2019Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
10596000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
676000
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-8000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-127248000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-28784000
CY2020Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201602Member
CY2020Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
183000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1509000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
111000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-176381000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1616000
CY2020Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-110000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-205303000
CY2020Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
205743000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1895000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-59000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
18257000
us-gaap Profit Loss
ProfitLoss
-93627000
us-gaap Profit Loss
ProfitLoss
-62914000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1546000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
807000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-450000
us-gaap Share Based Compensation
ShareBasedCompensation
5020000
us-gaap Share Based Compensation
ShareBasedCompensation
1737000
pstx Change In Fair Value Of Contingent Liabilities
ChangeInFairValueOfContingentLiabilities
6679000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
387000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-492000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-638000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-615000
pstx Imputed Rent Expense
ImputedRentExpense
44000
us-gaap Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
855000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2277000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-134000
pstx Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
3117000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
137000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1534000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-3979000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1043000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
8980000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
5653000
pstx Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-2681000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1055000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83013000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47954000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
14756000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3769000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
295147000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
66496000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
57500000
us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
17500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-252403000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-52765000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
186000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
205743000
pstx Net Proceeds From Grant
NetProceedsFromGrant
4163000
pstx Net Proceeds From Grant
NetProceedsFromGrant
4642000
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
10000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
329000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
53000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
313903000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
164357000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-21513000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
63638000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87784000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30395000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66271000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94033000
pstx Noncash Investing And Financing Activities Issuance Of Common Stock For Acquisition
NoncashInvestingAndFinancingActivitiesIssuanceOfCommonStockForAcquisition
10596000
pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
1715000
pstx Purchases Of Property And Equipment Included In Accounts Payable And Accrued Liabilities
PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedLiabilities
794000
us-gaap Construction In Progress Expenditures Incurred But Not Yet Paid
ConstructionInProgressExpendituresIncurredButNotYetPaid
2052000
pstx Conversion Of Redeemable Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering
ConversionOfRedeemableConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
326313000
us-gaap Interest Paid Net
InterestPaidNet
2349000
us-gaap Interest Paid Net
InterestPaidNet
1905000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
0
CY2020Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
0
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
1271000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
387000
pstx Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Stockholders Equity Deficit
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInStockholdersEquityDeficit
-1658000
CY2017Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
300000
CY2020Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
46809523
CY2020Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
42953085
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, which include, but are not limited to, estimates related to accrued expenses, contingent consideration, warrant liability, stock-based compensation expense, deferred tax valuation allowances and, prior to the Company&#8217;s IPO, the fair value of common stock. The Company bases its estimates on historical experience and other market-specific or relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the IPO, the Company utilized significant estimates and assumptions in determining the fair value of its common stock. The Company has utilized various valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants Technical Practice Aid, <font style="font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation, </font>to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including the prices at which the Company sold shares of preferred stock and the superior rights, preferences and privileges of the preferred stock relative to the common stock; the Company&#8217;s stage of development and material risks related to its business; the progress of the Company&#8217;s research and development programs, including the status and results of preclinical studies for its product candidates and progress of its development of manufacturing processes; external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry; the Company&#8217;s results of operations and financial position, including its levels of available capital resources, outstanding debt and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#8217;s common stock and preferred stock; the likelihood of achieving a liquidity event, such as an IPO or sale of the Company in light of prevailing market conditions; the hiring of key personnel; and the analysis of IPOs and the market performance of publicly traded companies in the biopharmaceutical industry, as well as recently completed mergers and acquisitions of peer companies. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date. </p>
CY2020Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
42953085
CY2020Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
326313000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
325893000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
106266000
CY2020Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
326313000
CY2020Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
34445108
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-86500000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-64400000
CY2020Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
341500000
us-gaap Variable Lease Payment
VariableLeasePayment
0
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
27283000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
12867000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3555000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2009000
us-gaap Depreciation
Depreciation
1500000
us-gaap Depreciation
Depreciation
800000
CY2020Q3 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
16135000
CY2019Q4 pstx Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
7993000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4815000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3283000
CY2020Q3 pstx Accrued Lease Cancellation Fee Payable Current
AccruedLeaseCancellationFeePayableCurrent
528000
CY2019Q4 pstx Accrued Lease Cancellation Fee Payable Current
AccruedLeaseCancellationFeePayableCurrent
979000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2837000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1671000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
325932000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
106247000
CY2019Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTax
19000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
39000
CY2019Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
222173000
CY2019Q4 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
26411194
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
4564000
CY2020Q3 pstx Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
24956000
us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote.
CY2020Q3 pstx Common Stock Dividends Declared
CommonStockDividendsDeclared
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3611030
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1245612
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.026
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.79
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
178037
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
112788
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4565817
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.87
CY2020Q3 us-gaap Area Of Land
AreaOfLand
83000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4565817
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1694101
CY2020Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P111M
us-gaap Operating Lease Expense
OperatingLeaseExpense
4400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1700000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.30
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.89
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.58
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.96
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
10.38
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.30
us-gaap Operating Lease Payments
OperatingLeasePayments
3600000
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.089
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1219000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4490000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4302000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4431000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y10M20D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7781000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
7781000
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6409000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
600000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1895000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
676000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5019000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1737000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
23800000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
43962000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
14148000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
29814000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2662000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3954000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4259000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
4377000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
4505000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
24638000
CY2019Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
44395000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-34414000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20954000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-93627000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-62914000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4686939
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28743561

Files In Submission

Name View Source Status
0001564590-20-053578-index-headers.html Edgar Link pending
0001564590-20-053578-index.html Edgar Link pending
0001564590-20-053578.txt Edgar Link pending
0001564590-20-053578-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
grug3sn3342s000001.jpg Edgar Link pending
pstx-10q_20200930.htm Edgar Link pending
pstx-20200930.xml Edgar Link completed
pstx-20200930.xsd Edgar Link pending
pstx-20200930_cal.xml Edgar Link unprocessable
pstx-20200930_def.xml Edgar Link unprocessable
pstx-20200930_lab.xml Edgar Link unprocessable
pstx-20200930_pre.xml Edgar Link unprocessable
pstx-ex311_9.htm Edgar Link pending
pstx-ex312_8.htm Edgar Link pending
pstx-ex321_6.htm Edgar Link pending
pstx-ex322_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending